Bristol-Myers Squibb Company
- Industrie
- Pharmaceuticals
- Bourse
- États-Unis
- Pays / Région
- USA
- Date d'introduction en bourse
- 1 janvier 1972
- Effectif
- 32 500
- Site web
- www.bms.com
Fourchette de valorisation composite · prudent $45–$52 / raisonnable $52–$70 / optimiste $80–$105. À $62.56, Dans la fourchette de valeur intrinsèque raisonnable.
À la publication $59.46 (24 mai 2026)
Données EODHD, présentées dans la devise de reporting ; à titre indicatif uniquement, ne constitue pas un conseil en investissement.
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers products for oncology, hematology, immunology, cardiovascular, and neuroscience indications. Its products include Opdivo for anti-cancer indications; Opdivo Qvantig, a subcutaneous PD-1 inhibitor for solid tumors; Orencia for active rheumatoid arthritis and psoriatic arthritis; Yervoy for the treatment of unresectable or metastatic melanoma; Reblozyl to treat anemia; Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Opdualag to treat unresectable or metastatic melanoma; and Camzyos for the treatment of symptomatic obstructive HCM. The company also offers Zeposia to treat relapsing forms of multiple sclerosis; Abecma for the treatment of patients with relapsed or refractory multiple myeloma; Sotyktu to treat moderate-to-severe plaque psoriasis; Krazati for the treatment of KRASG12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC); and Cobenfy to treat schizophrenia. In addition, it offers Eliquis for the reduction of risk of stroke/systemic embolism and for the treatment of DVT/PE; Revlimid, an oral immunomodulatory drug for multiple myeloma; Pomalyst/Imnovid for multiple myeloma; Sprycel for Philadelphia chromosome-positive chronic myeloid leukemia; and Abraxane to treat breast cancer. Further, the company provides Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC, as well as NSCLC and pancreatic cancer. It sells its products to wholesalers, distributors, specialty pharmacies, retailers, hospitals, clinics, and government agencies. The company has a strategic collaboration with Arcus Biosciences, Inc. to develop a treatment regimen that delivers tumor control in kidney cancer. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in Princeton, New Jersey.
Historique
Bristol-Myers Squibb Company, formerly known as Bristol-Myers Company, was founded in 1887 and is headquartered in Princeton, New Jersey, with an IPO date of January 1, 1972. The 2019 consolidation of Celgene reshaped its scale, lifting revenue from $26.1B in 2019 to $46.2B in 2022. Around 2024 the company completed several large acquisitions, including Karuna (total consideration of about $14B), Mirati (about $4.8B net cash plus a CVR), and RayzeBio (about $4.1B).
Position dans le secteur
Bristol-Myers Squibb is a large-cap biopharmaceutical company in the Healthcare sector (Drug Manufacturers - General) with about 32,500 employees, positioned as a first-tier global drugmaker spanning oncology, hematology, immunology, cardiovascular and neuroscience. 2025 total revenue was $48.19B, with the Growth Portfolio at $26.409B (about 55% of revenue); Eliquis generated $14.443B and Opdivo about $10B. R&D expense in 2025 was $9.951B. Broad competitors include Merck, AbbVie, Pfizer and Eli Lilly, with Merck's Keytruda a rival in immuno-oncology.
Pas encore d'analyse sur cette valeur dans votre langue.